



**AWTTC**

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund  
Medicines Recommended by NICE and AWMSG  
Health Board Formulary Status  
(From 01 October 2024 to 30 September 2025)



## BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable, and certainly within 60 calendar days of the publication of the decision. Commencement of the 60 days is the date known as the 'NTF start date'. For National Institute for Health and Care Excellence (NICE) recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD)/Final Draft Guideline (FDG), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For All Wales Medicines Strategy Group (AWMSG) recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60-day timescale may be delayed. In such circumstances the 'NTF start date' aligns with the date that the delaying reason has been resolved. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, The New Treatment Fund – Access to medicines recommended by NICE and AWMSG (WHC [2017] 001). From May 2024 these directions are further revised to enable the granting, in specific circumstances, of an extension to the standard 60-day timescale. This is detailed at:-

<https://www.gov.wales/directions-new-treatment-fund-exemptions>.

A formulary is an official list of medicines which may be prescribed within the health board or NHS trust to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use. Velindre University NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended over a 12-month period, commencing at least 14 months prior to the publication of this report. This is to account for the generally applicable 60-day period available to health boards and NHS trust to add these medicines to their formularies. Where an extended timescale has been authorised the data reporting system has been adapted to accommodate the variations.

## SOURCE OF INFORMATION

This report has been compiled through an analysis of health board and trust submitted data to the All Wales Therapeutics and Toxicology Centre (AWTTC).

In exceptional circumstances some medicines data have been removed from this report in light of specific factors outside the control of health boards and NHS trust.

Data extracted 16/12/2025






Key		On formulary within required timescale		On formulary outside of required timescale		Not on formulary but within required timescale
		Not on formulary and outside of required timescale		Not applicable to Velindre		

Table 1. Formulary status for New Treatment Fund medicines

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID3770 (TA1012)	Avapritinib	Mastocytosis	03 Oct 24								
155	Galsulfase	Mucopolysaccharidosis	09 Oct 24								
371	Miglustat	Niemann-Pick type C disease	09 Oct 24								
ID6333 (TA1015)	Teclistamab	Multiple myeloma	10 Oct 24								
ID6190 (TA996)	Linzagolix	Uterine fibroids	14 Oct 24								
ID5094 (TA1017)	Pembrolizumab	Lung cancer	16 Oct 24								
ID6368 (TA1014)	Alectinib	Lung cancer	16 Oct 24								
ID5115 (TA1018)	Fedratinib	Disease-related splenomegaly or symptoms in myelofibrosis	17 Oct 24								
ID6331 (TA1016)	Elafibranor	Primary biliary cholangitis	22 Oct 24								
ID4026 (TA1023)	Elranatamab	Multiple myeloma	29 Oct 24								
ID6289 (TA1021)	Crizotinib	Lung cancer	31 Oct 24								
ID5088 (TA1010)	Danicopan	Extravascular haemolysis	04 Nov 24								
ID6140 (TA1019)	Crovalimab	Paroxysmal nocturnal haemoglobinuria	04 Nov 24								
ID6337 (TA1020)	Eplontersen	Transthyretin-related amyloidosis	27 Nov 24								
ID3932 (TA1011)	Belzutifan	Tumours associated with von Hippel-Lindau disease	28 Nov 24								
ID1441 (TA1027)	Tebentafusp	Uveal melanoma	03 Dec 24								
ID6350 (TA1025)	Ublituximab	Multiple sclerosis	10 Dec 24								
ID6220 (TA1030)	Durvalumab	Lung cancer	11 Dec 24								
ID3821 (TA1035)	Vadadustat	Symptomatic anaemia	12 Dec 24								
ID3812 (TA989)	Etranacogene dezaparvovec	Haemophilia B	13 Dec 24								
ID3907 (TA1037)	Pembrolizumab	Lung cancer	20 Dec 24								
ID6336 (TA1040)	Olaparib	Breast cancer	09 Jan 25								
ID1001 (TA1034)	Anhydrous sodium thiosulfate	Ototoxicity	13 Jan 25								
ID4024 (TA1031)	Vamorolone	Duchenne muscular dystrophy	14 Jan 25								
ID6280 (TA1045)	12 SQ-HDM	Allergic rhinitis	31 Jan 25								
ID6404 (TA1041)	Durvalumab	Lung cancer	03 Feb 25								
2566	Emtricitabine/tenofovir alafena..	HIV	17 Feb 25								
ID1651 (TA1050)	Fenfluramine	Lennox-Gastaut syndrome	20 Feb 25								
ID3887 (TA1048)	Lisocabtagene maraleucel	B-cell lymphoma	20 Feb 25								

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6405 (TA1049)	Blinatumomab	Lymphoblastic leukaemia	25 Feb 25								
ID4015 (TA1003)	Exagamglogene autotemcel	Transfusion-dependent beta-thalassaemia	11 Mar 25								
ID4016 (TA1044)	Exagamglogene autotemcel	Sickle cell disease	11 Mar 25								
ID6263 (TA1053)	Cladribine	Multiple sclerosis	12 Mar 25								
ID3982 (TA1057)	Relugolix-estradiol-norethister..	Endometriosis	13 Mar 25								
ID6130 (HST33)	Leniolisib	Phosphoinositide 3-kinase delta syndrome	14 Mar 25								
ID6302 (TA1005)	Futibatinib	Advanced cholangiocarcinoma	20 Mar 25								
ID6170 (TA1051)	Efanesoctocog alfa	Haemophilia A	24 Mar 25								
ID6340 (TA1056)	Molnupiravir	COVID-19	28 Mar 25								
ID6426 (TA1064)	Dostarlimab	Endometrial cancer	11 Apr 25								
ID6178 (TA1066)	Somapacitan	Growth hormone deficiency	16 Apr 25								
ID1136 (TA1065)	Ipilimumab	Colorectal cancer	28 Apr 25								
ID1136 (TA1065)	Nivolumab	Colorectal cancer	28 Apr 25								
ID3822 (TA993)	Burosumab	Hypophosphataemia	30 Apr 25								
ID6357 (TA1067)	Linzagolix	Endometriosis	01 May 25								
ID6334 (TA1059)	Brentuximab vedotin	Hodgkin lymphoma	14 May 25								
ID3963 (TA1070)	Spesolimab	Psoriasis	15 May 25								
ID6324 (TA1071)	Atezolizumab	Lung cancer	15 May 25								
ID6370 (TA1063)	Capivasertib	Breast cancer	15 May 25								
ID6225 (TA1036)	Elacestrant	Breast cancer	19 May 25								
ID1333 (TA1062)	Erdafitinib	Urothelial cancer	27 May 25								
5385	Ziconotide	Chronic pain	29 May 25								
6440	Guanfacine	ADHD	29 May 25								
6441	Abiraterone	Prostate cancer	29 May 25								
ID6244 (TA1080)	Mirikizumab	Crohn's disease	02 Jun 25								
ID6320 (TA1022)	Bevacizumab gamma	Wet age-related macular degeneration	02 Jun 25								
ID6411 (TA1075)	Dapagliflozin	Chronic kidney disease	03 Jun 25								
ID5120 (TA1043)	Osimertinib	Lung cancer	11 Jun 25								
ID6317	Durvalumab	Endometrial cancer	12 Jun 25								
ID6221 (TA1077)	Nemolizumab	Atopic dermatitis	18 Jun 25								
6561	Teriparatide	osteoporosis in men	20 Jun 25								
ID6342 (TA1073)	Marstacimab	Haemophilia A or B	23 Jun 25								
ID6392 (TA1081)	Zanubrutinib	Mantle cell lymphoma	27 Jun 25								
ID6274 (TA1079)	Fruquintinib	Colorectal cancer	03 Jul 25								
ID6293 (TA1042)	Selpercatinib	Lung cancer	04 Jul 25								

Reference	Medicine Name	Abbreviated Indication	NTF Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6328 (TA1060)	Osimertinib	Lung cancer	08 Jul 25								
ID6153 (TA1086)	Ribociclib	Breast cancer	18 Jul 25								
ID6462 (TA1087)	Betula verrucosa	Allergic rhinitis and/or conjunctivitis	21 Jul 25								
ID6308 (TA1074)	Sparsentan	Primary IgA nephropathy	23 Jul 25								
ID2725 (TA1090)	Tremelimumab	Hepatocellular carcinoma	29 Jul 25								
ID547 (TA1093)	Idebenone	Leber's hereditary optic neuropathy	08 Aug 25								
ID2725 (TA1090)	Durvalumab	Hepatocellular carcinoma	12 Aug 25								
ID6237 (ID1094)	Guselkumab	Ulcerative colitis	14 Aug 25								
ID6238 (TA1095)	Guselkumab	Crohn's disease	14 Aug 25								
ID5100 (TA1055)	Rucaparib	Ovarian, fallopian tube and peritoneal cancer	19 Aug 25								
ID3981 (TA1098)	Isatuximab	Multiple myeloma	04 Sept 25								
ID5073 (TA1099)	Durvalumab	Lung cancer	16 Sept 25								
ID6394 (TA1101)	Garadacimab	Hereditary angioedema	18 Sept 25								
ID4069 (TA1007)	Rucaparib	Ovarian, fallopian tube or peritoneal cancer	23 Sept 25								

End of Report